(PRCT) PROCEPT BioRobotics Corporation ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRCT) PROCEPT BioRobotics Corporation Complete Analysis Pack
Make Smarter Expansion Decisions with the Full Report
This PROCEPT BioRobotics Corporation Ansoff Matrix Analysis clarifies the company’s growth options—market penetration, market development, product development, and diversification—and shows how its robotic surgical platforms can be expanded or adapted; the page includes a genuine preview/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use analysis.
Market Penetration
Expand Aquablation use across the installed U.S. base
PROCEPT BioRobotics had 78 of 130 AquaBeam systems in the U.S. at year-end 2021, so the fastest market penetration move is still to drive more Aquablation cases through the installed base. Each added procedure lifts high-margin disposable revenue, since the system needs recurring single-use tools for every case. That makes surgeon training, hospital utilization, and referral capture the key volume levers.
Convert more BPH patients from legacy surgery
Aquablation therapy targets men with benign prostatic hyperplasia and lower urinary tract symptoms, so PROCEPT BioRobotics Corporation can win share from legacy surgery inside the same BPH market. In 2024, the company reported revenue growth above 40%, helped by more installed systems and rising procedure volumes. Every conversion from TURP or laser surgery is direct market penetration, not a new-market bet.
Raise surgeon credentialing in current accounts
PROCEPT BioRobotics can lift Market Penetration by credentialing more urologists and OR teams in current hospitals, since each trained user raises system use and case throughput. The company ended 2024 with over 500 AquaBeam systems installed, so deeper surgeon access inside the same accounts can scale utilization without adding new markets. More credentialed operators also lowers idle time and speeds repeat procedure adoption.
Increase utilization of current hospital placements
PROCEPT BioRobotics Corporation can grow faster by pushing more cases through each installed robot, because higher utilization spreads the capital cost over more procedures and lifts recurring Aquablation therapy sales. In 2025, that penetration play matters even more as hospitals protect budgets and prefer platforms that improve OR economics without adding new capital spend.
- More cases per robot
- Lower cost per procedure
- Higher recurring consumables pull-through
- Better hospital ROI and retention
Grow repeat disposable sales per procedure
Each Aquablation case adds recurring disposable revenue, so more cases in the same hospital network lift sales without new system placements. In FY2024, PROCEPT BioRobotics Corporation reported revenue of $224.8 million, showing how procedure volume, not just hardware, drives the model. This is the clearest market penetration lever after the install base is in place.
- More cases, same installed base.
- Disposable revenue repeats every procedure.
- Case growth scales margin and cash flow.
PROCEPT’s Growth Hinges on Driving More Aquablation Cases
PROCEPT BioRobotics Corporation’s Market Penetration strategy is to drive more Aquablation cases through its existing installed base. In 2024, revenue reached $224.8 million as procedure growth lifted recurring disposable sales. With over 500 AquaBeam systems installed by year-end 2024, deeper use of each system is the main near-term lever.
| Metric | Value |
|---|---|
| FY2024 revenue | $224.8 million |
| AquaBeam systems installed | 500+ |
| Penetration lever | More cases per system |
What is included in the product
Detailed Word Document
Analyzes PROCEPT BioRobotics Corporation’s growth strategy across existing and new products and markets using the Ansoff Matrix
Editable Excel File
Provides a clear PROCEPT BioRobotics Ansoff Matrix to quickly align growth priorities across products and markets.
Reference Sources
Provides a concise, vetted bibliography tying each Ansoff growth path for PROCEPT BioRobotics to traceable primary and secondary sources for fast, defensible decision-making.
Market Development
Extend AquaBeam beyond the U.S.-heavy base
AquaBeam is already deployed outside the U.S., but the U.S. still makes up the majority of PROCEPT BioRobotics Corporation systems, so more non-U.S. sales use the same product, not a new one. In FY2025, that makes this a clear market development move: take one cleared platform into more geographies. The play is expansion, not redesign.
Add more non-U.S. hospital systems
PROCEPT BioRobotics Corporation already has a non-U.S. footprint, which shows its AQUABEAM platform can be adopted outside the United States. Adding more hospital systems in those same markets is a direct market development move: same therapy, more sites, wider reach. It also scales a recurring capital-plus-disposable model without changing the core product.
Broaden access in new country markets
PROCEPT BioRobotics Corporation already sells beyond one country, so expanding AquaBeam and Aquablation into new national markets fits the Ansoff market development play. The product stays the same; only the geography changes, which can scale revenue without changing the core device. That matters in a urology market where approved, hospital-ready systems can move faster than new products.
Reach additional BPH referral channels
PROCEPT BioRobotics Corporation can expand Aquablation by building referral ties with community urologists and primary care clinicians, opening new patient sources for men with BPH-related lower urinary tract symptoms. This is classic new-market access with an existing product: the therapy stays the same, but the funnel widens beyond large academic centers.
- More referrals, same Aquablation therapy
- Targets men with BPH-LUTS
- Uses community urologists and clinicians
That matters because BPH is common in older men, so even small referral gains can lift procedure volume and recurring capital sales for PROCEPT BioRobotics Corporation.
Increase presence in additional care settings
PROCEPT BioRobotics Corporation can place the same BPH therapy in more urology offices, ASCs, and hospital outpatient sites, so it grows addressable demand without changing the product. BPH affects about 50% of men in their 50s and up to 90% in their 80s, so each new care setting widens access to the same patient pool.
- Same therapy, more treatment sites
- Expands geographic reach and channels
- Uses current product, not new R&D
This market development move can lift procedure volume faster than product change alone, because one installed system can serve more referral paths and more prostate procedure accounts.
PROCEPT’s Growth Story Is Global Expansion, Not New Products
PROCEPT BioRobotics Corporation’s market development is the same AquaBeam/Aquablation system pushed into more countries, care sites, and referral channels. In FY2025, the U.S. still drove most systems, so the growth lever is geographic and channel expansion, not new product design.
| Driver | FY2025 signal | Meaning |
|---|---|---|
| Non-U.S. sales | Minority of systems | Room to expand abroad |
| BPH market | 50% of men in 50s; 90% in 80s | Large same-product demand pool |
What You See Is What You Get
PROCEPT BioRobotics Corporation Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
Advance the next-generation robotic platform
PROCEPT BioRobotics Corporation’s product development strategy upgrades the AquaBeam Robotic System that delivers Aquablation therapy, keeping the company in the same urology market while refreshing the platform. The focus is clear: improve precision, workflow, and surgeon usability on a single core system.
This is a one-product-platform bet, with 2 core offerings tied together: AquaBeam Robotic System and Aquablation therapy. Next-gen hardware can lift repeat use, support higher procedure volumes, and defend share without moving outside urology.
Improve image guidance and planning software
Improve image guidance and planning software fits AquaBeam’s image-guided workflow, so current users can get better targeting without changing the core system. Smarter imaging and pre-op planning can cut setup friction and support more consistent treatment delivery. That makes the upgrade a low-friction way to deepen adoption inside the existing user base.
Expand disposable and accessory offerings
PROCEPT BioRobotics Corporation’s procedure-led model naturally supports recurring consumables, because each Aquablation case can pull through disposable and accessory items. Adding new single-use components around the installed base is product development: it grows value in the same market, not a new one. This also deepens stickiness, since every added accessory can lift case economics and repeat revenue per system.
Simplify Aquablation workflow steps
Simplifying Aquablation workflow steps at PROCEPT BioRobotics Corporation fits a practical product development move: hospitals want faster setup, and surgeons want less friction in the room. The Company Name platform already sits in a procedure-driven market, so small usability gains can matter more than big hardware changes when adoption depends on OR time and repeat use.
That matters because the system’s value is tied to efficiency, consistency, and throughput in current accounts, where even modest reductions in prep time can help defend utilization. Product refinements that make the Aquablation process easier to learn and quicker to run can support higher conversion inside installed sites without changing the core therapy.
- Lower setup time improves OR efficiency.
- Cleaner steps help surgeon adoption.
- Usability gains support existing accounts.
- Low-risk path for platform growth.
Broaden clinical evidence for the platform
Broader clinical evidence for PROCEPT BioRobotics Corporation can deepen physician trust in Benign Prostatic Hyperplasia treatment and support wider use of the same platform. More peer-reviewed data helps prove consistent outcomes, lower retreatment risk, and clearer patient selection, which strengthens product positioning in the core market.
- Supports physician adoption in BPH
- Reinforces clinical outcome claims
- Improves positioning without new markets
- Fits product-development strategy
PROCEPT Boosts Aquablation with Smarter Imaging and Simpler Workflow
PROCEPT BioRobotics Corporation’s product development stays on one core urology platform: AquaBeam Robotic System plus Aquablation therapy. The next step is better imaging, planning, workflow, and single-use accessories, which can lift adoption in the same market without a new category.
| Product move | Impact |
|---|---|
| Imaging and software upgrades | Better targeting |
| Workflow simplification | Faster OR use |
| Accessories and disposables | Higher repeat pull-through |
Diversification
No disclosed non-urology product line
As of July 2026, PROCEPT BioRobotics Corporation still relies on one core platform, Aquablation, for urology and BPH, with 0 disclosed non-urology product lines. That means diversification is weak: the company’s revenue base stays tied to 1 specialty and 1 procedure set, so any true expansion beyond urology remains unproven.
Core focus remains Aquablation for BPH
PROCEPT BioRobotics’ diversification is still low: Aquablation for BPH remains the flagship and the main revenue engine. In FY2024, Company Name reported $199.8 million in revenue, up 61% year over year, and the business identity still centers on robotic, image-guided treatment of male BPH. That is concentration, not broad spread across new markets.
Global growth still uses the same therapy
PROCEPT BioRobotics Corporation’s international push still centers on the same AquaBeam and Aquablation platform, so it is geographic expansion, not product diversification. That matters because the company is still selling one therapy family into the same urology use case, with no new category added. In FY2025, the core story remains the same: more countries, same treatment, same clinical platform.
Revenue remains tied to systems and disposables
PROCEPT BioRobotics Corporation still relies on one therapy: urology. Its system placements and procedure-linked disposables are different revenue streams, but both depend on Aquablation adoption, so this is not true diversification. In FY2025, that concentration kept growth tied to the same clinical and reimbursement cycle.
- Two streams, one product category
- Systems drive installed base
- Disposables depend on procedures
- Urology concentration stays high
Adjacency stays within the same specialty
PROCEPT BioRobotics Corporation still looks urology-led: its core platform is Aquablation therapy for benign prostatic hyperplasia, so the growth path stays inside the same specialty. There is no clear evidence here of a separate new market with a separate new product, so diversification is not a major visible strategy.
That means adjacency, not true diversification, is the better read. Any expansion still appears tied to robotic urology workflows, where PROCEPT BioRobotics Corporation can deepen use in the same clinician base and care setting.
- Core market: urology
- Core product: Aquablation
- New market not supported
- New product not supported
PROCEPT Still Tied to One Therapy in FY2025
PROCEPT BioRobotics Corporation’s diversification remains weak in FY2025: Aquablation still drives the business, with $199.8 million FY2024 revenue and no disclosed non-urology product lines. International growth adds geography, not a new product market, so the company is still concentrated in 1 therapy family.
| Metric | FY2025/FY2024 |
|---|---|
| Core therapy | Aquablation |
| Revenue | $199.8M FY2024 |
| Non-urology lines | 0 disclosed |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.